Abstract
BackgroundCrohn’s disease (CD) treatments and associated adverse events (AEs) can be burdensome for patients. However, specific values which quantify the impact on health-related quality of life (HRQL) for economic evaluation are lacking.ObjectivesThis study aimed to elicit health utility values for AEs related to biologic treatment and surgical complications for CD in the UK.MethodsHealth states were developed by literature review and interviews with CD patients (n=6) and gastroenterologists (n=3). Draft health states were validated in cognitive debrief interviews with patients (n=4) and gastroenterologists (n=2). Treatment AEs were described with moderate-severe CD (reference state) and included hypersensitivity, injection site reactions, serious infection, lymphoma, and tuberculosis. Surgical complications were described following bowel surgery (reference state) and included anastomotic leak, wound infection, prolonged ileus/bowel obstruction, and intra-abdominal abscess. Health states were valued by 100 members of the general public who completed background questions, EQ-5D-3L, visual analogue scale rating task and time trade-off (TTO) interviews.ResultsThe mean TTO value for reference states ‘moderate to severe CD’ and ‘bowel surgery’ were 0.70 (SD=0.28) and 0.69 (SD=0.28). Participants rated lymphoma as the worst AE/surgical complication state (0.44, SD=0.37), followed by tuberculosis (0.47, SD=0.85) and anastomotic leak (0.48, SD=0.38). Values of other AE/surgical complication states ranged from 0.76 (hypersensitivity) to 0.56 (intra-abdominal abscess).ConclusionsThis study provides utility estimates for AE and surgical complication health states not previously assessed in the context of CD. As new treatments are emerging, it is important to include these influences on quality of life in any economic evaluation of treatments.
Highlights
Crohn’s disease (CD) treatments and associated adverse events (AEs) can be burdensome for patients
The current study estimates utility values/disutilities associated with treatment for CD
The health state vignettes described AEs related to biologic treatment and surgery-related complications in moderate to severe CD patients in the UK
Summary
Crohn’s disease (CD) treatments and associated adverse events (AEs) can be burdensome for patients. Crohn’s disease (CD) is a chronic inflammatory bowel disease and currently affects at least 115 000 people in the UK.[1,2] Symptoms of active CD include diarrhea, abdominal pain, and gastrointestinal bleeding, and this can have a substantial impact on patients’ health-related quality of life (HRQL).[3] disease activity is a good predictor of HRQL, people who are asymptomatic can report reduced HRQL, higher anxiety about risks and AEs, and worse coping than other bowel conditions such as ulcerative colitis.[4] Up to a third of people with CD are diagnosed before age of 21 years there is lack of research on treatments for the young population.[5,6] This can be problematic as this is the time when young adults are deciding upon their career, education and other goals
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
